AssetMark Inc’s Madrigal Pharmaceuticals MDGL Stock Holding History

AssetMark Inc’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.24M	Sell	4,181 -208	-5%	-$107K	﹤0.01%	925
2026 Q1	$2.3M	Sell	4,389 -421	-9%	-$201K	﹤0.01%	855
2025 Q4	$2.8M	Sell	4,810 -248	-5%	-$127K	0.01%	776
2025 Q3	$2.32M	Buy	5,058 +160	+3%	+$59.7K	0.01%	779
2025 Q2	$1.48M	Sell	4,898 -285	-5%	-$84.9K	﹤0.01%	837
2025 Q1	$1.72M	Buy	5,183 +1,003	+24%	+$330K	﹤0.01%	756
2024 Q4	$1.29M	Buy	4,180 +238	+6%	+$66.9K	﹤0.01%	801
2024 Q3	$837K	Buy	3,942 +303	+8%	+$77.5K	﹤0.01%	813
2024 Q2	$1.02M	Buy	+3,639	New	+$866K	﹤0.01%	759

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AssetMark Inc's MDGL Position: Q2 2026 in Review

AssetMark Inc reduced its Madrigal Pharmaceuticals (MDGL) stake by 4.7% in Q2 2026, selling an estimated $107K and leaving 4,181 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #925.

AssetMark Inc first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.8M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

AssetMark Inc held 4,181 shares of Madrigal Pharmaceuticals worth $2.24M as of Q2 2026.
AssetMark Inc sold 208 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $107K.
Madrigal Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #925 holding.
AssetMark Inc first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
AssetMark Inc's Madrigal Pharmaceuticals position peaked at $2.8M in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.